{
    "clinical_study": {
        "@rank": "21926", 
        "arm_group": {
            "arm_group_label": "Treatment (O6-benzylguanine, carmustine)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive O6-benzylguanine IV over 1 hour followed by topical carmustine once every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial is studying the side effects and best dose of carmustine given together\n      with O(6)-benzylguanine in treating patients with stage I or stage II cutaneous T-cell\n      lymphoma that has not responded to previous treatment. Drugs used in chemotherapy use\n      different ways to stop cancer cells from dividing so they stop growing or die. Combining\n      more than one drug may kill more cancer cells"
        }, 
        "brief_title": "O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma", 
        "condition": [
            "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", 
            "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", 
            "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Cutaneous"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the kinetics of AGT depletion in CTCL skin lesions. II. To determine the\n      toxicity of low dose BCNU plus O6BG.\n\n      OUTLINE: This is a dose-escalation study of carmustine.\n\n      Patients receive O6-benzylguanine IV over 1 hour followed by topical carmustine once every 2\n      weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\n      Cohorts of 3-6 patients receive escalating doses of carmustine until the maximum tolerated\n      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6\n      patients experience dose-limiting toxicity.\n\n      Patients are followed for 6 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed CTCL, stages IA-IIA\n\n          -  Performance status ECOG grade 0, 1, or 2\n\n          -  Patients must have recovered from toxicity of prior treatment and have received no\n             CTCL therapy other than emoliation for at least 4 weeks\n\n          -  Patients must have signed a consent form indicating the investigational nature of the\n             treatment and its potential side effects\n\n          -  WBC > 4,000/ul\n\n          -  ANC > 2,000/ul\n\n          -  Platelets > 100,000/ul\n\n          -  Bilirubin < 1.5 mg/dL\n\n          -  SGOT within normal range\n\n          -  Prothrombin time within normal range\n\n          -  Creatinine =< 1.5 mg/dL or creatinine clearance >= 70 ml/min\n\n          -  Calcium and electrolytes normal\n\n          -  Glucose-controlled (diet and insulin) diabetes is permitted\n\n          -  DLCO > 80% normal with the exception of patients who demonstrate clinically normal\n             lung function based on history, physical examination, and chest x-ray as interpreted\n             by the principal investigator\n\n          -  Only those patients with biopsiable tumor and willing to undergo several biopsies\n             will be eligible\n\n          -  Must have failed 1 conventional treatment other than topical corticosteroids; this\n             includes UVB, PUVA, topical mechlorethamine, electron beam, photopheresis,\n             chemotherapy and immuno-modulatory agents such as cytokines\n\n        Exclusion Criteria:\n\n          -  Patients with a prior treatment with a nitrosourea\n\n          -  Patients with known central nervous system involvement or primary CNS malignancies\n             will be ineligible\n\n          -  Patients with performance status ECOG grade 3 or 4\n\n          -  Pregnant women, women who are breast feeding infants, or women with reproductive\n             potential not practicing adequate contraception, because of potential toxicity to the\n             fetus or infant\n\n          -  Patients with active infection\n\n          -  Patients with pulmonary disease as determined by history, physical examination, chest\n             X-ray or pulse oximetry\n\n          -  CTCL patients with stage IIB-IVB disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003613", 
            "org_study_id": "NCI-2012-03119", 
            "secondary_id": [
                "CWRU 6496", 
                "U01CA062502"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (O6-benzylguanine, carmustine)", 
                "description": "Given IV", 
                "intervention_name": "O6-benzylguanine", 
                "intervention_type": "Drug", 
                "other_name": "BG"
            }, 
            {
                "arm_group_label": "Treatment (O6-benzylguanine, carmustine)", 
                "description": "Given topically", 
                "intervention_name": "carmustine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BCNU", 
                    "BiCNU", 
                    "bis-chloronitrosourea"
                ]
            }, 
            {
                "arm_group_label": "Treatment (O6-benzylguanine, carmustine)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carmustine", 
                "O(6)-benzylguanine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44106"
                }, 
                "name": "Case Western Reserve University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Trial of O6 Benzylguanine and BCNU in Cutaneous T-cell Lymphoma", 
        "overall_official": {
            "affiliation": "Case Western Reserve University", 
            "last_name": "Kevin Cooper", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Point and interval estimates of response using the binomial distribution will be obtained using data from patients with measurable or evaluable disease. If responses occur, then the mean and median duration of response will be determined. Statistical significance will be determined using the t test for analysis of continuous data.", 
                "measure": "Percent decrease of AGT in CTCL skin lesions, obtained from tissue samples", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 weeks"
            }, 
            {
                "description": "Toxicities will be recorded and tabulated. Additional point and interval estimates for the MTD will be obtained using the methods of logistic regression of the proportion of patients experiencing a dose-limiting toxicity of grade >= 2 and by conventional regression of the mean dose-limiting toxicities on dose level.", 
                "measure": "MTD of carmustine estimated as the dose level which is one level below where >= 2 DLT are observed", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003613"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 1999", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }, 
    "geocoordinates": {
        "Case Western Reserve University": "41.499 -81.695"
    }
}